Molecular and cellular immune mediators of neuroprotection

Molecular Neurobiology

Volumn 34, Issue 3, 2006, Pages 221-242

  Turrin, Nicolas P ^a,b   Rivest, Serge ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cytokines; Demyelination; Inflammation; Innate immunity; Neurodegeneration; Neurotrophins; Repair

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; CASPASE 6; CASPASE 7; DEXAMETHASONE; ERYTHROPOIETIN; ESTROGEN; ETHIDIUM BROMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIN; NEUROTROPHIN 4; NITROPRUSSIDE SODIUM; ONCOMODULIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN; TESTOSTERONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFARCTION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CYTOKINE RELEASE; DNA DAMAGE; DRUG BLOOD LEVEL; HEMATOPOIETIC STEM CELL; HUMAN; HUNTINGTON CHOREA; IMMUNITY; INNATE IMMUNITY; MEDIATOR; MEDIATOR RELEASE; MICROGLIA; MONOCYTE; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; SPINAL CORD INJURY; STROKE; TRANSCRIPTION REGULATION;

EID: 33847043183     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/MN:34:3:221     Document Type: Article

References (101)

1. Dirnagl U., Iadecola C., and Moskowitz M. A. (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22, 391-397.
2. Lo E. H., Dalkara T., and Moskowitz M. A. (2003) Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci. 4, 399-415.
3. Gasic G. P. and Nicotera P. (2003) To die or to sleep, perhaps to dream. Toxicol. Lett. 139, 221-227.
4. Nixon R. A. (2006) Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends Neurosci. 9, 528-535.
5. Akwa Y., Allain H., Bentue-Ferrer D., et al. (2005) Neuroprotection and neurodegenerative diseases: from biology to clinical practice. Alzheimer Dis. Assoc. Disord. 19, 226-239.
6. Ekshyyan O. and Aw T. Y. (2004) Apoptosis: a key in neurodegenerative disorders. Curr. Neurovasc. Res. 1, 355-371.
7. Hawkins R. A., O'Kane R. L., Simpson I. A., and Vina J. R. (2006) Structure of the blood-brain barrier and its role in the transport of amino acids. J. Nutr. 136, 218S-226S.
8. Hawkins B. T. and Davis T. P. (2005) The blood-brain barrier/ neurovascular unit in health and disease. Pharmacol. Rev. 57, 173-185.
9. Turrin N. P. and Rivest S. (2004) Unraveling the molecular details involved in the intimate link between the immune and neuroendocrine systems. Exp. Biol. Med. (Maywood). 229, 996-1006.
10. Buller K. M. (2001) Role of circumventricular organs in pro-inflammatory cytokine-induced activation of the hypothalamic-pituitary-adrenal axis. Clin. Exp. Pharmacol. Physiol. 28, 581-589.
11. Kielian T. (2006) Toll-like receptors in central nervous system glial inflammation and homeostasis. J. Neurosci. Res. 83, 711-730.
12. Anderson K. V. (2000) Toll signaling pathways in the innate immune response. Curr. Opin. Immunol. 12, 13-19.
13. Kaur C., Hao A. J., Wu C. H., and Ling E. A. (2001) Origin of microglia. Microsc. Res. Tech. 54, 2-9.
14. Simard A. R. and Rivest S. (2004). Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J. 18, 998-1000.
15. Massengale M., Wagers A. J., Vogel H., and Weissman I. L. (2005) Hematopoietic cells maintain hematopoietic fates upon entering the brain. J. Exp. Med. 201, 1579-1589.
16. Priller J., Flugel A., Wehner T., et al. (2001) Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat. Med. 7, 1356-1361.
17. Simard A. R., Soulet D., Gowing G., Julien J. P., and Rivest S. (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489-502.
18. Dong Y. and Benveniste E. N. (2001) Immune function of astrocytes. Glia 36, 180-190.
19. Lubetzki C., Williams A., and Stankoff B. (2005) Promoting repair in multiple sclerosis: problems and prospects. Curr. Opin. Neurol. 18, 237-244.
20. Engelhardt B. and Ransohoff R. M. (2005) The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26, 485-495.
21. Olson J. K., Ludovic Croxford J., and Miller S. D. (2004) Innate and adaptive immune requirements for induction of autoimmune demyelinating disease by molecular mimicry. Mol. Immunol. 40, 1103-1108.
22. Vilhardt F. (2005) Microglia: phagocyte and glia cell. Int. J. Biochem. Cell. Biol. 37, 17-21.
23. Nadeau S. and Rivest S. (2003) Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J. Neurosci. 23, 5536-5544.
24. Rudehill S., Muhallab S., Wennersten A., et al. (2006) Autoreactive antibodies against neurons and basal lamina found in serum following experimental brain contusion in rats. Acta. Neurochir. (Wien). 148, 199-205.
25. Ciric B., Howe C. L., Paz Soldan M., et al. (2003) Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. Brain Pathol. 13, 608-616.
26. Glezer I., Lapointe A., and Rivest S. (2006) Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries. FASEB J. 20, 750-752.
27. Turrin N. P. and Rivest S. (2006) Tumor necrosis factor alpha but not interleukin 1 beta mediates neuroprotection in response to acute nitric oxide excitotoxicity. J. Neurosci. 26, 143-151.
28. Marchetti L., Klein M., Schlett K., Pfizenmaier K., and Eisel U. L. (2004). Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NFkappa B pathway. J. Biol. Chem. 279, 32,869-32,881.
29. Arnett H. A., Mason J., Marino M., Suzuki K., Matsushima G. K., and Ting J. P. (2001) TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 4, 1116-1122.
30. Blais V. and Rivest S. (2004) Effects of TNFalpha and IFN-gamma on nitric oxide-induced neurotoxicity in the mouse brain. J. Immunol. 172, 7043-7052.
31. Fontaine V., Mohand-Said S., Hanoteau N., Fuchs C., Pfizenmaier K., and Eisel U. (2002) Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF). in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J. Neurosci. 22, RC216.
32. Kennedy S. G., Kandel E. S., Cross T. K., and Hay N. (1999) Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol. Cell Biol. 19, 5800-5810.
33. Guo Z., Iyun T., Fu W., Zhang P., and Mattson M. P. (2004) Bone marrow transplantation reveals roles for brain macrophage/microglia TNF signaling and nitric oxide production in excitotoxic neuronal death. Neuromolecular Med. 5, 219-234.
34. Dhandapani K. M., Wade F. M., Wakade C., Mahesh V. B., and Brann D. W. (2005) Neuroprotection by stem cell factor in rat cortical neurons involves AKT and NFkappaB. J. Neurochem. 95, 9-19.
35. Bartesaghi S., Marinovich M., Corsini E., Galli C. L., and Viviani B. (2005) Erythropoietin: a novel neuroprotective cytokine. Neurotoxicology. 26, 923-928.
36. Sakanaka M., Wen T. C., Matsuda S., et al. (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. USA. 95, 4635-4640.
37. Brines M. L., Ghezzi P., Keenan S., et al. (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. USA. 97, 10,526-10,531.
38. Celik M., Gokmen N., Erbayraktar S., et al. (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc. Natl. Acad. Sci. USA. 99, 2258-2263.
39. Ehrenreich H., Hasselblatt M., Dembowski C., et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8, 495-505.
40. Siren A. L., Fratelli M., Brines M., et al. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. USA. 98, 4044-4049.
41. Chong Z. Z., Lin S. H., Kang J. Q., and Maiese K. (2003) Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J. Neurosci. Res. 71, 659-669.
42. Ghezzi P. and Brines M. (2004) Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ. 11(Suppl 1), S37-S44.
43. Viviani B., Bartesaghi S., Corsini E., et al. (2005) Erythropoietin protects primary hippocampal neurons increasing the expression of brainderived neurotrophic factor. J. Neurochem. 93, 412-421.
44. Mitrasinovic O. M., Grattan A., Robinson C. C., et al. (2005) Microglia overexpressing the macrophage colony-stimulating factor receptor are neuroprotective in a microglial-hippocampal organotypic coculture system. J. Neurosci. 25, 4442-4451.
45. Berezovskaya O., Maysinger D., and Fedoroff S. (1996) Colony stimulating factor-1 potentiates neuronal survival in cerebral cortex ischemic lesion. Acta Neuropathol. (Berl). 92, 479-486.
46. Vincent V. A., Robinson C. C., Simsek D., and Murphy G. M. (2002) Macrophage colony stimulating factor prevents NMDA-induced neuronal death in hippocampal organotypic cultures. J. Neurochem. 82, 1388-1397.
47. Ahmad A. S., Ahmad M., de Brum-Fernandes A. J., and Dore S. (2005) Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res. 1066, 71-77.
48. Liu D., Wu L., Breyer R., Mattson M. P., and Andreasson K. (2005) Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann. Neurol. 57, 758-761.
49. McCullough L., Wu L., Haughey N., et al. (2004) Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 24, 257-268.
50. Bilak M., Wu L., Wang Q., et al. (2004) PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann. Neurol. 56, 240-248.
51. Ahmad A. S., Saleem S., Ahmad M., and Dore S. (2006) Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol. Sci. 89, 265-270.
52. Liang X., Wang Q., Hand T., et al. (2005) Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J. Neurosci. 25, 10,180-10,187.
53. Toyomoto M., Ohta M., Okumura K., et al. (2004) Prostaglandins are powerful inducers of NGF and BDNF production in mouse astrocyte cultures. FEBS Lett. 562, 211-215.
54. Bazan N. G., Marcheselli V. L., and Cole-Edwards K. (2005) Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann. NY Acad. Sci. 1053, 137-147.
55. Filbin M. T. (2006) How inflammation promotes regeneration. Nat. Neurosci. 9, 715-717.
56. Yin Y., Henzl M. T., Lorber B., et al. (2006) Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat. Neurosci. 9, 843-852.
57. Kalb R. (2005) The protean actions of neurotrophins and their receptors on the life and death of neurons. Trends Neurosci. 28, 5-11.
58. Royo N. C., Conte V., Saatman K. E., et al. (2006) Hippocampal vulnerability following traumatic brain injury: a potential role for neurotrophin-4/5 in pyramidal cell neuroprotection. Eur. J. Neurosci. 23, 1089-1102.
59. Leeds P., Leng Y., Chalecka-Franaszek E., and Chuang D. M. (2005) Neurotrophins protect against cytosine arabinoside-induced apoptosis of immature rat cerebellar neurons. Neurochem. Int. 46, 61-72.
60. McCollum A. T. and Estus S. (2004) NGF acts via p75 low-affinity neurotrophin receptor and calpain inhibition to reduce UV neurotoxicity. J. Neurosci. Res. 77, 552-564.
61. Sharma H. S. (2003) Neurotrophic factors attenuate microvascular permeability disturbances and axonal injury following trauma to the rat spinal cord. Acta Neurochir. Suppl. 86, 383-388.
62. Majdan M. and Miller F. D. (1999) Neuronal life and death decisions functional antagonism between the Trk and p75 neurotrophin receptors. Int. J. Dev. Neurosci. 17, 153-161.
63. Longo F. M. and Massa S. M. (2004) Neurotrophin-based strategies for neuroprotection. J. Alzheimers Dis. 6, S13-S17.
64. Levy D. E. and Lee C. K. (2002) What does Stat3 do? J. Clin. Invest. 109, 1143-1148.
65. Naumann T., Schnell O., Zhi Q., et al. (2003) Endogenous ciliary neurotrophic factor protects GABAergic, but not cholinergic, septohippocampal neurons following fimbria-fornix transection. Brain Pathol. 13, 309-321.
66. Vanderlocht J., Hellings N., Hendriks J. J., et al. (2006) Leukemia inhibitory factor is produced by myelin-reactive T cells from multiple sclerosis patients and protects against tumor necrosis factor-alpha-induced oligodendrocyte apoptosis. J. Neurosci. Res. 83, 763-774.
67. Zang da W. and Cheema S. S. (2003) Leukemia inhibitory factor promotes recovery of locomotor function following spinal cord injury in the mouse. J. Neurotrauma. 20, 1215-1222.
68. Pizzi M., Sarnico I., Boroni F., et al. (2004) Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices. Mol. Cell Neurosci. 25, 301-311.
69. Adcock I. M., Ito K., and Barnes P. J. (2004) Glucocorticoids: effects on gene transcription. Proc. Am. Thorac. Soc. 1, 247-254.
70. Glezer I. and Rivest S. (2004) Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist 10, 538-552.
71. Sloka J. S. and Stefanelli M. (2005) The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult. Scler. 11, 425-432.
72. Mihai C. and Jubelt B. (2005) Post-infectious encephalomyelitis. Curr. Neurol. Neurosci. Rep. 5, 440-445.
73. Kurkowska-Jastrzebska I., Litwin T., Joniec I., et al. (2004) Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int. Immunopharmacol. 4, 1307-1318.
74. Hall E. D. and Springer J. E. (2004) Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 1, 80-100.
75. Qian T., Guo X., Levi A. D., Vanni S., Shebert R. T., and Sipski M. L. (2005) High-dose methyl-prednisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord. 43, 199-203.
76. Alderson P. and Roberts I. (2005) Corticosteroids for acute traumatic brain injury. Cochrane Database Syst. Rev. CD000196.
77. Amantea D., Russo R., Bagetta G., and Corasaniti M. T. (2005) From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens. Pharmacol. Res. 52, 119-132.
78. Alonso de Lecinana M. and Egido J. A. (2006) Estrogens as neuroprotectants against ischemic stroke. Cerebrovasc. Dis. 21(Suppl 2), 48-53.
79. Won C. K., Kim M. O., and Koh P. O. (2006) Estrogen modulates Bcl-2 family proteins in ischemic brain injury. J. Vet. Med. Sci. 68, 277-280.
80. Alexaki V. I., Charalampopoulos I., Kampa M., et al. (2006) Activation of membrane estrogen receptors induce pro-survival kinases. J. Steroid Biochem. Mol. Biol. 98, 97-110.
81. D'Astous M., Mickley K. R., Dluzen D. E., and Di Paolo T. (2005) Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice. Neuroendocrinology 82, 111-120.
82. D'Astous M., Mendez P., Morissette M., Garcia-Segura L. M., and Di Paolo T. (2006) Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol. Pharmacol. 69, 1492-1498.
83. Veiga S., Azcoitia I., and Garcia-Segura L. M. (2005) Extragonadal synthesis of estradiol is protective against kainic acid excitotoxic damage to the hippocampus. Neuroreport 16, 1599-1603.
84. Soucy G., Boivin G., Labrie F., and Rivest S. (2005) Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J. Immunol. 174, 6391-6398.
85. Behl C. (2006) The search for novel avenues for the therapy and prevention of Alzheimer's disease. Drug News Perspect. 19, 5-12.
86. Frye C. A. and McCormick C. M. (2000) Androgens are neuroprotective in the dentate gyrus of adrenalectomized female rats. Stress 3, 185-194.
87. Coers S., Tanzer L., and Jones K. J. (2002) Testosterone treatment attenuates the effects of facial nerve transection on glial fibrillary acidic protein (GFAP) levels in the hamster facial motor nucleus. Metab. Brain Dis. 17, 55-63.
88. Markianos M., Panas M., Kalfakis N., and Vassilopoulos D. (2005) Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia. Ann. Neurol. 57, 520-525.
89. Nguyen T. V., Yao M., and Pike C. J. (2005) Androgens activate mitogen-activated protein kinase signaling: role in neuroprotection. J. Neurochem. 94, 1639-1651.
90. Dantzer R., Bluthe R. M., and Kelley K. W. (1991) Androgen-dependent vasopressinergic neurotransmission attenuates interleukin-1-induced sickness behavior. Brain Res. 557, 115-120.
91. Chapman G. A., Moores K., Harrison D., Campbell C. A., Stewart B. R., and Strijbos P. J. (2000) Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J. Neurosci. 20, RC87.
92. Verge G. M., Milligan E. D., Maier S. F., Watkins L. R., Naeve G. S., and Foster A. C. (2004) Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur. J. Neurosci. 20, 1150-1160.
93. Mizuno T., Kawanokuchi J., Numata K., and Suzumura A. (2003) Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 979, 65-70.
94. De Simone R., Ajmone-Cat M. A., and Minghetti L. (2004) Atypical antiinflammatory activation of microglia induced by apoptotic neurons: possible role of phosphatidylserine-phosphatidylserine receptor interaction. Mol. Neurobiol. 29, 197-212.
95. Latchman D. S. (2004) Protective effect of heat shock proteins in the nervous system. Curr. Neurovasc. Res. 1, 21-27.
96. Vabulas R. M., Wagner H., and Schild H. (2002) Heat shock proteins as ligands of toll-like receptors. Curr. Top. Microbiol. Immunol. 270, 169-184.
97. Li Y., Field P. M., and Raisman G. (1999) Death of oligodendrocytes and microglial phagocytosis of myelin precede immigration of Schwann cells into the spinal cord. J. Neurocytol. 28, 417-427.
98. Di Bello I. C., Dawson M. R., Levine J. M., and Reynolds R. (1999) Generation of oligodendroglial progenitors in acute inflammatory demyelinating lesions of the rat brain stem is associated with demyelination rather than inflammation. J. Neurocytol. 28, 365-381.
99. Tatsumi K., Haga S., Matsuyoshi H., Inoue M., Manabe T., Makinodan M., and Wanaka A. (2005) Characterization of cells with proliferative activity after a brain injury. Neurochem. Int. 46, 381-389.
100. Lesniak M. S., Kelleher E., Pardoll D., and Cui Y. (2005) Targeted gene therapy to antigen-presenting cells in the central nervous system using hematopoietic stem cells. Neurol. Res. 27, 820-826.
101. Werner P. (2003) Knowledge about symptoms of Alzheimer's disease: correlates and relationship to help-seeking behavior. Int. J. Geriatr. Psychiatry 18, 1029-1036.